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order pharmacy. Dispensing fees were deducted from the com-
munity pharmacy cost to estimate the average drug product cost
per day supply. Drug product cost per day supply was multiplied
by the modeled days supply in mail order to estimate the drug
product cost in mail order. The effect of mail order was estimated
by therapeutic class. A multivariate sensitivity analysis was per-
formed. RESULTS: In the period August, 2000 to July, 2001, 4.1
million drug treatments were initiated; of those, 758 thousand
(18.7%) were selected based on the criteria set in the study for
use of mail order. The use of mail order resulted in 6.3% more
days supply and 6.4% more drug product cost than in commu-
nity pharmacy. The therapeutic classes with the lowest increase
in drug product cost were immunosuppressants (4.8%), cardio-
vascular agents (4.9%) and smooth muscle relaxants (5.5%).
Results were sensitive to changes in the assumptions of minimum
day’s supply of the treatment, adherence rate, and the number
of ﬁll in community pharmacy before mail order was initiated.
CONCLUSIONS: Mail order pharmacy increased drug utiliza-
tion. Mail order could lead to an increase in Medicaid drug
expenditures if the mail order reimbursement formula does not
discount the effect of increased drug utilization.
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OBJECTIVES: This research determines the effects of higher
brand and generic drug copays on drug utilization, the price elas-
ticity of drug demand in a commercially insured population.
METHODS: Drug utilization variables and health status indica-
tors are computed separately for each full year of enrollment
under a speciﬁc copay structure. Fixed effect estimation is per-
formed with the ﬁrst difference estimator to obtain the marginal
effect of copay change on net drug cost and number of pre-
scriptions. Data were provided by a major West Coast pharmacy
beneﬁt management company. The sample consists of all insur-
ance claims for employees, their spouses, and their dependents,
under age 65, who were enrolled continuously for two years.
Enrollees worked in a small California ﬁrm—a ﬁrm with 2–50
employees—that offered only one health plan. The ﬁnal sample
has 30,824 enrollees working in 4554 small ﬁrms. RESULTS:
Higher generic drug copay leads to a reduction in number of 
prescriptions (-0.23; p < 0.0001) and total net cost to the insurer
(-$7.06; p < 0.0001). Higher brand copay only results in lower
total net cost to the insurer (-$2.5; p < 0.0001). The generic 
price elasticity for total net cost is -0.16, and brand price elas-
ticity for total net cost is -0.11. CONCLUSION: Enrollees
decrease their drug use when faced with higher copays and health
plans can signiﬁcantly reduce their outlays on drugs by raising
drug copays.
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OBJECTIVES: To document the current level of need for med-
ications among currently underinsured elderly individuals and to
describe the medical conditions that lead to hospitalizations in
this group. METHODS: This study utilizes a unique data base
containing “quasi-claims” data on 5303 Maryland residents 65
years of age or older who received free drugs from Patient Assis-
tance Programs (PAPs). MEDBANK, a program that helps low-
income individuals cope ﬁnancially by assisting them in applying
for free-drug programs, maintains an internal data base on the
drugs requested and those that were received. This data base
makes it possible to identify the drugs that were requested and
received by this group for which no claims data base exists.
Elderly MEDBANK recipients are then matched to the state of
Maryland inpatient discharge data base to identify the diagnoses
for which these individuals were hospitalized. RESULTS: The
most frequently requested drugs were cardiovascular agents,
which account for 42% of all requests. Commensurate with that
result, we ﬁnd that the top primary diagnosis for hospitalizations
of this population was for diseases of the circulatory system. The
least accessible drugs were anti-infective systemic agents, for
which patients received only 34% of their requests. Overall,
MEDBANK recipients received 59% of the drugs requested. 
The median patient received about two-thirds of their requests,
while the median number of drugs requested and received,
respectively, were six and three. CONCLUSIONS: PAPs allowed
Maryland Medicare eligible individuals to receive only 59% of
the drugs they requested, highlighting the need for additional
coverage.
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OBJECTIVE: The pharmacy’s recorded days supply variable is
frequently used in outcomes research to estimate a prescription’s
intended period of use, but little is published on factors that
might inﬂuence its validity. We examined the effect of a change
in copayment structure on the accuracy of the days supply ﬁeld
of a prescription records database. METHODS: Prior to January
1, 2002, Kaiser Permanente Northwest enrollees were able to
obtain a 90-day supply of medication for one copay. After this
date, a copay was required for each 30-day medication supply.
We collected dispensing data for oral antidiabetic medications
from January 1, 1996-December 31, 1997 (90-day copay), and
from January 1, 2002–December 31, 2002 (30-day copay).
Accuracy of the recorded days supply variable was compared to
a gold standard (calculated by pharmacist (KS) interpreting 
each prescription’s directions for use. RESULTS: There were
3155 and 1495 records in the 90-day copay and 30-day copay
periods, respectively. The mean difference (±SD) between gold
standard and recorded days supply under the 90-day copay was
0.92 days (±24.3); 72.8% were in complete agreement, 10.7%
were +1 to +30 days different, 5.2% were -1 to -30 days dif-
ferent, maximum range of -200 to 370 days different. The 
mean difference (±SD) under the 30-day copay was -0.33
(±10.8) days; 88.3% were in complete agreement, 9.1% were +1
to +30 days different, and 5.1% were -1 to -30 days different,
range of -90 to +90 days different. CONCLUSION: After
requiring additional copayments for a 90-day supply, the phar-
macy’s recorded days supply was more likely to be in agreement
with the directions for use. Both pharmacy staff and enrollees
may have contributed to the improvement by verifying that
copays were accurate. When both provider and enrollee have a
ﬁnancial interest, prescription days supply data may be more
accurate.
